Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7945 and Linvoseltamab in Relapsed/Refractory Multiple Myeloma
NCT06669247Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Nov 2033
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of REGN7945 in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Dec 2024; status: recruiting.
02
Drugs
REGN7945
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06669247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669247.